Final results of the DAPS (denosumab adherence preference satisfaction) study: A 24-month, randomized, crossover comparison with alendronate in postmenopausal women

Osteoporosis International

Volumn 23, Issue 1, 2012, Pages 317-326

  Freemantle, N ^a,e   Satram Hoang, S ^b   Tang, E T ^b   Kaur, P ^b,f   MacArios, D ^b   Siddhanti, S ^a   Borenstein, J ^c   Kendler, D L ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b AMGEN INC   (United States)

^c Cedars Sinai Health System   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Alendronate; Compliance; Denosumab; Persistence

Indexed keywords

ALENDRONIC ACID; DENOSUMAB;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BONE DENSITY; BONE MINERAL; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR FRACTURE; FEMUR NECK; FRACTURE; HUMAN; INJECTION; JAW OSTEONECROSIS; LOGISTIC REGRESSION ANALYSIS; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOARTHRITIS; PAIN; PATIENT SATISFACTION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZATION; TABLET; TREATMENT OUTCOME; WOMEN'S HEALTH;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT PREFERENCE; RANK LIGAND; TREATMENT OUTCOME;

EID: 84857361266     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1780-1     Document Type: Article

References (29)

1. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and metaanalysis. Osteoporos Int 21:1943-1951
2. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493-1501 (Pubitemid 350211697)
3. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022 (Pubitemid 44175011)
4. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202-210
5. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008 (Pubitemid 40064656)
6. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928 (Pubitemid 44498580)
7. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB (2009) Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 15:728-740
8. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J (2005) Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 43:1203-1207 (Pubitemid 43012177)
9. Byer B, Myers LB (2000) Psychological correlates of adherence to medication in asthma. Psychol Health Med 5:389-393
10. Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J (2004) Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with nonadherence to HAART. Int J STD AIDS 15:38-44 (Pubitemid 38096128)
11. Kendler DL, Bessette L, Hill CD et al (2010) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 21:837-846
12. Fallowfield L, Atkins L, Catt S et al (2006) Patients' preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17:205-210 (Pubitemid 43160107)
13. Granger AL, Fehnel SE, Hogue SL, Bennett L, Edin HM (2006) An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. J Affect Disord 90:217-221 (Pubitemid 43183531)
14. Reginster JY, Rabenda V, Neuprez A (2006) Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38:S2-S6
15. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618-625 (Pubitemid 41614462)
16. Bekker PJ, Holloway DL, Rasmussen AS et al (2004) A singledose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066 (Pubitemid 41110556)
17. McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831 (Pubitemid 43290920)
18. Lewiecki EM, Miller PD, McClung MR et al (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832-1841 (Pubitemid 351229299)
19. Brown JP, Prince RL, Deal C et al (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153-161
20. Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756-765
21. Kendler DL, McClung MR, Freemantle N et al (2011) Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 22:1725-1735
22. Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14:1-24
23. Gold DT, Horne R, Hill C, Borenstein J, Varon S,Macarios D (2008) Development, reliability, and validity of a new preference satisfaction questionnaire (PSQ). J Bone Miner Res 23:S210-S211
24. Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA (2010) Adherence and occurrence of fractures after switching to once-monthly oral bisphophonates. Pharmacoepidemiol Drug Saf 19:1233-1240
25. Rodan G, Reszka A, Golub E, Rizzoli R (2004) Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 20:1291-1300 (Pubitemid 39120794)
26. Black DM, Schwartz AV, Ensrud KE et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938 (Pubitemid 46021497)
27. Gallagher AM, Rietbrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569-1575
28. Ström O, Borgström F, Kanis JA, Jönsson B (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20:23-34
29. Jönsson B, Ström O, Eisman JA et al (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967-982